Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Other Working Capital Changes (2016 - 2026)

Pharma-Bio Serv's Other Working Capital Changes history spans 17 years, with the latest figure at -$39716.0 for Q1 2026.

  • For Q1 2026, Other Working Capital Changes fell 5.24% year-over-year to -$39716.0; the TTM value through Jan 2026 reached -$310291.0, down 1021.4%, while the annual FY2025 figure was -$308312.0, 1527.7% down from the prior year.
  • Other Working Capital Changes reached -$39716.0 in Q1 2026 per PBSV's latest filing, up from -$336215.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $220778.0 in Q3 2022 to a low of -$336215.0 in Q4 2025.
  • Average Other Working Capital Changes over 5 years is -$2863.1, with a median of $11453.0 recorded in 2023.
  • The largest YoY upside for Other Working Capital Changes was 439.29% in 2025 against a maximum downside of 683.46% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $197507.0 in 2022, then tumbled by 167.55% to -$133410.0 in 2023, then soared by 143.19% to $57624.0 in 2024, then crashed by 683.46% to -$336215.0 in 2025, then skyrocketed by 88.19% to -$39716.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Other Working Capital Changes are -$39716.0 (Q1 2026), -$336215.0 (Q4 2025), and $96317.0 (Q3 2025).